Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH’s Blood
Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency. The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency
Pharming Group N.V. announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood, the peer-reviewed international medical journal of the American Society of Hematology. Data from this study was previously announced on February 2, 2022.
“As we continue to seek a better understanding of APDS as a recently characterized rare disease, we remain committed to sharing our findings with researchers and doctors around the world."
- Anurag Relan MD, MPH | Chief Medical Officer